Nonalcoholic fatty liver disease (NAFLD), a global public health problem in recent years with an incidence rate of approximately 25%, may bring a progressive disease of non-alcoholic steatohepatitis (NASH), cirrhosis, or even hepatocellular carcinoma (Fan et al., 2017; Younossi, 2019). Ever greater attention has been paid to treating NAFLD, and except for the crucial intervention of lifestyle modification, the treatments of drugs and health products have become particularly important in our current world of fast-paced modern life (Zhu et al., 2020). At present, the main adjuvant clinical therapies usually include pioglitazone and vitamin E treatment, but the applicability of these is weak because the long-term effects have yet to be determined (Majumdar et al., 2021). So far, no drugs specifically targeting NAFLD have been approved by the FDA. People have been exploring drugs to treat NAFLD over the past two decades.

Substances from plants including tea, flaxseed, cinnamon, silybin, soy, ginger, and licorice are playing an increasingly promising role in the treatment and prevention of NAFLD (Yan et al., 2020). However, previous research was much more focused on plant-derived extracts or mixtures, which due to the unclear constituents or the lack of standardized product progress, is still a long way from drug development. Therefore, this Research Topic, Nonalcoholic Fatty Liver Disease Therapy; Exploring Molecular Mechanisms of Well-defined Composition from Natural Plants, is inclined to and encourages pharmacological research about NAFLD using well-defined compositions. We hope to discover and collect novel
natural compounds, active ingredients, combination formulas, or prescriptions in plants with therapeutic selectivity that can be used for NAFLD, or NASH. Meanwhile, the novel discovery of molecular pathogenic mechanisms of NAFLD studies was also reported.

In this Research Topic, the aurantio-obtusin from Cassia semen (Zhou et al.), pterostilbene from blueberries and grapes (Tan et al.), the combination of bicyclol from Schisandra chinensis and berberine from Coptis chinensis and Berberis vulgaris (Li et al.), artemether from artemisinin (Xu et al.), scoparone from Artemisia scoparia Waldst. et Kit and Artemisia capillaris Thunb. (Jiang et al.), nootkatone from Alpiniae oxyphylla Fructus (Yong et al.), Limonin from lemon (Wang et al.) and theaflavin-3,3′-digallate from black tea (Zhou et al.), attenuated NAFLD/NASH mainly by regulating lipid metabolism and liver inflammation to varying degrees. There are also a lot of new pathways involved. For example, Aurantio-obtusin ameliorates hepatic steatosis via AMPK/autophagy- and AMPK/TFEB-mediated suppression of lipid accumulation; bicyclol enhanced lipolysis and β-oxidation through restoring the p62-Nrf2-CE2S signaling axis and p62-Nrf2-PPARα signaling axis, respectively; scoparone downregulated the activation of JNK/Sab signaling, improved hepatosteatosis and inflammation, especially mitochondrial dysfunction; theaflavin-3,3′-digallate was speculated to attenuate leptin-deficient induced NAFLD via Fads1/PPARβ/ Fabp4 axis. In particular, berberine and theaflavin-3,3′-digallate also protected NAFLD in vivo through regulating gut microbiota which is a hot issue of concern, for example, berberine enriches lipid metabolism-related Bacteroidaceae (family) and Bacteroides (genus); theaflavin-3,3′-digallate increased the abundance of Prevotellaceae_UCG-001, norank_f_Ruminococcaceae, and GCA-900066575 and significantly decreased that of Parvibacter. Noticeably, with the multiple targets, the ganweikang tablet (Ma et al.), based on traditional Chinese medicine theory and clinical experience, was verified to improve NAFL and NASH by modulating inflammation, apoptosis, and fatty acid oxidation by inhibiting NFκB, caspase-8, and activating PPARα. In addition, artemether, the combination of bicyclol and berberine, and pterostilbene, also mediated the development of liver fibrosis in vivo, which protects liver injury more broadly. These results have a direct impact on the treatment of NAFLD and provided promising candidates for its therapy.

The pathophysiological mechanisms of NAFLD is a complex, "multiple-hit theory" that has gradually been posited to explain the pathogenesis of NAFLD, including visceral obesity and lipodystrophy-like phenotype, diabetes, insulin resistance, de novo lipogenesis, gut dysbiosis, genetic factors, epigenetic modifications, etc (Zhang et al., 2022). Great progress has been made on the alleviating effect of plant-derived composition on fatty liver disease, but the research on its mechanism is not comprehensive and in-depth, and its clinical application needs to be evaluated based on the “multiple-hit theory”.

Author contributions

WZ wrote the draft, MH and RL revised and polished the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (grant number 81903319); the Special Fund for Scientific Innovation Strategy-Construction of High Level Agriculture of Academy Science (grant number R2018Y1-YB3002); the Foundation of Director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Fan, J. G., Kim, S. U., and Wong, V. W. (2017). New trends on obesity and NAFLD in Asia. J. Hepatol. 67, 862–873. doi:10.1016/j.jhep.2017.06.003

Majumdar, A., Verbeek, J., and Tsochatzis, E. A. (2021). Non-alcoholic fatty liver disease: Current therapeutic options. Curr. Opin. Pharmacol. 61, 98–105. doi:10.1016/j.coph.2021.09.007

Yan, T., Yan, N., Wang, P., Xia, Y., Hao, H., Wang, G., et al. (2020). Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm. Sin. B 10, 3–18. doi:10.1016/j.apsb.2019.11.017

Younossi, Z. M. (2019). Non-alcoholic fatty liver disease - a global public health perspective. J. Hepatol. 70, 531–544. doi:10.1016/j.jhep.2018.10.033

Zhang, W., Lin, H., Cheng, W., Huang, Z., and Zhang, W. (2022). Protective effect and mechanism of plant-based monoterpenoids in non-alcoholic fatty liver diseases. J. Agric. Food Chem. 70, 4839–4859. doi:10.1021/acs.jafc.2c00744

Zhu, J. Z., Yi, H. W., Huang, W., Pang, T., Zhou, H. P., and Wu, X. D. (2020). Fatty liver diseases, mechanisms, and potential therapeutic plant medicines. Chin. J. Nat. Med. 18, 161–168. doi:10.1016/S1875-5364(20)30017-0